Name: Malaysian Ivermectin Study Inconclusive
Uploaded: 2022-02-19T03:19:21+00:00
Duration: 37 min 34 s
Description: Malaysian Ivermectin Study Inconclusive A study from Malaysia for Ivermectin vs. standard of care shows in significant efficacy in any of its primary or secondary outcomes. Let's review the data. If y

2 years ago

198

Malaysian Ivermectin Study Inconclusive

A study from Malaysia for Ivermectin vs. standard of care shows in significant efficacy in any of its primary or secondary outcomes. Let's review the data.

If you like this content and want more, I am doing a special lifetime membership offer. Click here:
https://www.drbeen.com/yt-special/

Want to support this work?:
Buy me a coffee :-) https://www.buymeacoffee.com/DrMobeenSyed
Become my patron: https://www.patreon.com/mobeensyed?fan_landing=true
PayPal: https://paypal.me/mobeensyed?locale.x=en_US

#drbeen #koolbeens #COVID

Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

URL list from Friday, Feb. 18 2022

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial | Critical Care Medicine | JAMA Internal Medicine | JAMA Network
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2789362

ioi220006va_1644957302.1595.png (3011×1698)
https://cdn.jamanetwork.com/ama/content_public/journal/intemed/0/ioi220006va_1644957302.1595.png?Expires=1648255758&Signature=N8G8Cff1bwPM~-vD2bpfeAOmT~-olY2v1TOEShUchIKWfuFKZ-v3vQ~jv0GwXTCWr0MzO5CyKgVPiuqVmtqUc-xokAXWDKm~zmtnu8cVAg2wR2FwNMlyCb5ewjzrm1doTKGoy3Vt5zmOCWpd-M0VphlhdBvAMg1f91obZ76eVsUFbHoD6MdBf0HJt2ksfHotkMVsj4yp~WyTMJi4ywU1tcpd77p~QpcgYNz5pakXFlpVhddxWnqgR3pptjdXB9bvmCmf9uKLXiFZm4KuJk1gnNDd9UGgdP~CIU0aTHefTJlre0h5BqRsb5iEUYkEH51mREPZAFPNgV0F-m9ED0rLRw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA

Coronavirus (COVID-19) Update: FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant | FDA
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review - PMC
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8627269/

The FDA delays considering the Pfizer COVID vaccine for kids under age 5 : NPR
https://www.npr.org/2022/02/11/1080204817/the-fda-delays-considering-the-pfizer-covid-vaccine-for-kids-under-age-5

Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine | Pfizer
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-ongoing-studies-covid-19

Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA | Pfizer
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-emergency

Loading comments...